HC Wainwright Has Negative Forecast for KYTX FY2024 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for shares of Kyverna Therapeutics in a research note issued on Wednesday, November 20th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3.14) per share for the year, down from their previous estimate of ($3.01). HC Wainwright has a “Neutral” rating and a $6.00 price objective on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.77) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.01. The company had revenue of $0.01 million for the quarter.

Other research analysts have also recently issued reports about the stock. Rodman & Renshaw started coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $16.00 target price on the stock. JPMorgan Chase & Co. cut their price objective on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Wells Fargo & Company lowered their price target on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. UBS Group initiated coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They issued a “buy” rating and a $13.00 target price for the company. Finally, RODMAN&RENSHAW raised Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Kyverna Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.71.

Kyverna Therapeutics Trading Down 3.2 %

NASDAQ KYTX opened at $3.99 on Friday. Kyverna Therapeutics has a 1 year low of $3.94 and a 1 year high of $35.06. The company has a fifty day moving average price of $5.28 and a 200-day moving average price of $8.24.

Institutional Trading of Kyverna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD purchased a new position in Kyverna Therapeutics during the 1st quarter worth $23,093,000. Novo Holdings A S grew its holdings in shares of Kyverna Therapeutics by 150.0% during the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company’s stock worth $13,125,000 after buying an additional 1,050,000 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in Kyverna Therapeutics in the 2nd quarter worth about $1,421,000. Great Point Partners LLC raised its position in shares of Kyverna Therapeutics by 232.8% in the 2nd quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock worth $3,744,000 after buying an additional 349,152 shares during the period. Finally, Janus Henderson Group PLC acquired a new stake in shares of Kyverna Therapeutics in the first quarter worth $15,041,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.